COURTNAY KINCAID: Open Payments
NPI 1740765023 · POCAHONTAS, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$221 in 12 payments from 8 companies in 2025. Trend: 2023 $403 · 2024 $358 · 2025 $221
Food & beverage: $221
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 4 | $66 |
| ABBVIE INC. | 1 | $31 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $30 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 2 | $17 |
| Novo Nordisk Inc | 1 | $17 |
| GlaxoSmithKline, LLC. | 1 | $14 |
Products named: FARXIGA, UBRELVY, CAPLYTA, Auvelity, GEMTESA, VOQUEZNA, Ozempic, AIRSUPRA.
Industry payments across AR — which companies pay providers there.
